Close
Close

Alnylam Pharmaceuticals - Familial amyloid polyneuropathy

Partner

Not provided

Rare Disease

Familial amyloid polyneuropathy

Sponsor

Alnylam Pharmaceuticals

Access Program Information

The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).

Contact

Contact: Alnylam EAP Hotline ((617) 715-0200)

Locations
  • United States
  • Iowa City, Iowa, United States
  • United States
  • New Orleans, Louisiana, United States
  • United States
  • Baltimore, Maryland, United States
  • United States
  • Boston, Massachusetts, United States
  • United States
  • Pittsburgh, Pennsylvania, United States

Free Newsletter